
Pre-made Bermekimab benchmark antibody ( Whole mAb, anti-IL1A therapeutic antibody, Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-063
Pre-Made Bermekimab biosimilar, Whole mAb, Anti-IL1A Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-063-1mg | 1mg | 3090 | ||
GMP-Bios-ab-063-10mg | 10mg | 21890 | ||
GMP-Bios-ab-063-100mg | 100mg | 148000 | ||
GMP-Bios-ab-063-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Bermekimab biosimilar, Whole mAb, Anti-IL1A Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha therapeutic antibody |
INN Name | Bermekimab |
Target | IL1A |
Format | Whole mAb |
Derivation | |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Preregistration |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2018 |
Year Recommended | 2019 |
Companies | XBiotech Inc. |
Conditions Approved | na |
Conditions Active | Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer |
Conditions Discontinued | Haematological malignancies |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
